Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 5
1976 2
1977 1
1978 2
1979 1
1980 4
1981 6
1982 2
1983 7
1984 3
1985 4
1986 6
1987 3
1988 4
1989 5
1990 4
1991 8
1992 5
1993 11
1994 5
1995 15
1996 10
1997 12
1998 17
1999 31
2000 23
2001 37
2002 29
2003 34
2004 24
2005 42
2006 42
2007 37
2008 34
2009 42
2010 40
2011 48
2012 49
2013 60
2014 65
2015 61
2016 67
2017 69
2018 60
2019 70
2020 110
2021 94
2022 72
2023 64
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

1,312 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Stage III Skin Cancer"
Page 1
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). Garbe C, et al. Eur J Cancer. 2022 Jul;170:236-255. doi: 10.1016/j.ejca.2022.03.008. Epub 2022 May 12. Eur J Cancer. 2022. PMID: 35570085 Free article. Review.
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology …
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A …
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malvehy J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, van Akkooi ACJ, Lorigan P, Garbe C, Lebbé C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Gauci ML, et al. Eur J Cancer. 2022 Aug;171:203-231. doi: 10.1016/j.ejca.2022.03.043. Epub 2022 Jun 19. Eur J Cancer. 2022. PMID: 35732101 Free article. Review.
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. ...Histopathology (small-cell neuroendocrine appearance) and immunohistochemistry (CK20 positivity and TTF-1 negativity) confirm the diagnosis. The current …
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. ...Histopatholog …
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Gershenwald JE, et al. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. CA Cancer J Clin. 2017. PMID: 29028110 Free PMC article.
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnos …
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a lar …
Melanoma surgery-An update.
Wollina U. Wollina U. Dermatol Ther. 2022 Dec;35(12):e15966. doi: 10.1111/dth.15966. Epub 2022 Nov 16. Dermatol Ther. 2022. PMID: 36336954 Review.
Cutaneous melanoma is the major cause of mortality from all skin cancers. The treatment has been revolutionized in recent years by introduction of immunotherapy and targeted therapy for melanoma patients Stages III and IV. ...
Cutaneous melanoma is the major cause of mortality from all skin cancers. The treatment has been revolutionized in recent years by in …
Guidelines of care for the management of primary cutaneous melanoma.
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Swetter SM, et al. J Am Acad Dermatol. 2019 Jan;80(1):208-250. doi: 10.1016/j.jaad.2018.08.055. Epub 2018 Nov 1. J Am Acad Dermatol. 2019. PMID: 30392755
The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Dermatology clinical pr …
The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer …
Targeted therapeutic strategies for melanoma.
Zhang S, Xie R, Zhong A, Chen J. Zhang S, et al. Chin Med J (Engl). 2023 Dec 20;136(24):2923-2930. doi: 10.1097/CM9.0000000000002692. Epub 2023 May 6. Chin Med J (Engl). 2023. PMID: 37144745 Free PMC article. Review.
The incidence of melanoma continues to rise, and now melanoma accounts for 1.7% of cancer diagnoses worldwide and is the fifth most common cancer in the United States. ...Patients who were originally stage III or IV inoperable have the opportunity to a …
The incidence of melanoma continues to rise, and now melanoma accounts for 1.7% of cancer diagnoses worldwide and is the fifth most c …
Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Hieken TJ, et al. Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390614. doi: 10.1200/EDBK_390614. Am Soc Clin Oncol Educ Book. 2023. PMID: 37116111 Free article.
Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with or without in-transit metastases, represents approximately 15% of new melanoma diagnoses every year with additional cases presenting as recurrent nodal disease following previous …
Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with or without in-transit metastases, repr …
Considering adjuvant therapy for stage II melanoma.
Poklepovic AS, Luke JJ. Poklepovic AS, et al. Cancer. 2020 Mar 15;126(6):1166-1174. doi: 10.1002/cncr.32585. Epub 2019 Dec 23. Cancer. 2020. PMID: 31869447 Free PMC article. Review.
It has now been confirmed that these classes of agents have a benefit for patients with stage III melanoma after surgical resection, and anti-PD1 and BRAF/MEK inhibitors are standards of care in this setting. Some patients with stage II disease (lymph node-ne …
It has now been confirmed that these classes of agents have a benefit for patients with stage III melanoma after surgical rese …
Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial.
Menzies SW, Sinz C, Menzies M, Lo SN, Yolland W, Lingohr J, Razmara M, Tschandl P, Guitera P, Scolyer RA, Boltz F, Borik-Heil L, Herbert Chan H, Chromy D, Coker DJ, Collgros H, Eghtedari M, Corral Forteza M, Forward E, Gallo B, Geisler S, Gibson M, Hampel A, Ho G, Junez L, Kienzl P, Martin A, Moloney FJ, Regio Pereira A, Ressler JM, Richter S, Silic K, Silly T, Skoll M, Tittes J, Weber P, Weninger W, Weiss D, Woo-Sampson P, Zilberg C, Kittler H. Menzies SW, et al. Lancet Digit Health. 2023 Oct;5(10):e679-e691. doi: 10.1016/S2589-7500(23)00130-9. Lancet Digit Health. 2023. PMID: 37775188 Free article. Clinical Trial.
BACKGROUND: Diagnosis of skin cancer requires medical expertise, which is scarce. Mobile phone-powered artificial intelligence (AI) could aid diagnosis, but it is unclear how this technology performs in a clinical scenario. ...INTERPRETATION: The mobile phone-powere …
BACKGROUND: Diagnosis of skin cancer requires medical expertise, which is scarce. Mobile phone-powered artificial intelligence …
Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
Rhodin KE, Jung SH, Elleson K, DePalo D, Straker R, McKinley S, Beekman K, Parker L, Chen S, Iyer MK, Salama AKS, Bartlett E, Karakousis G, Zager JS, Tyler DS, Beasley GM. Rhodin KE, et al. Ann Surg Oncol. 2023 Oct;30(11):6340-6352. doi: 10.1245/s10434-023-13935-0. Epub 2023 Jul 22. Ann Surg Oncol. 2023. PMID: 37481487
Herein, we investigated the impact of time to adjuvant ICI on survival in patients with stage III melanoma. METHODS: Patients with resected stage III melanoma receiving adjuvant immune therapy were identified within a multi-institutional retrospective …
Herein, we investigated the impact of time to adjuvant ICI on survival in patients with stage III melanoma. METHODS: Patients …
1,312 results